Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients

Update Il y a 4 ans
Reference: NCT00533442

Woman and Man

Extract

This study was designed to determine which immunosuppressive agent, rapamycin or mycophenalate mofetil, resulted in better outcome in patients with type 1 diabetes and renal failure, who presented for a kidney-pancreas transplant.


Inclusion criteria

  • Type 1 Diabetes

Links